SCHEMBL279929

SCHEMBL279929

Cc1ccc(C(=O)COCc2ccncc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.47
CASP3 P42574 2/20 0.47
SENP8 Q96LD8 2/20 0.47
SENP7 Q9BQF6 2/20 0.47
SENP6 Q9GZR1 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
RAB9A P51151 6/20 0.42
NPC1 O15118 5/20 0.42
DAO P14920 1/20 0.41
GRM5 P41594 5/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CDC7 O00311 1/20 0.38
DBF4 Q9UBU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27907453 0.77 ALDH1A1 (0.60) POLBCASP3SENP8SENP7SENP6
SCHEMBL280048 0.76 POLB (0.43) POLBCASP3SENP8SENP7SENP6
SCHEMBL280130 0.75 NPC1 (0.44) POLBCASP3SENP8SENP7SENP6
SCHEMBL280197 0.74 RAB9A (0.48) POLBCASP3SENP8SENP7SENP6
SCHEMBL279743 0.73 NPC1 (0.41) POLBCASP3SENP8SENP7SENP6
SCHEMBL8233855 0.73 GRM5 (0.46) GRM5KMT2AHTT
SCHEMBL279733 0.72 GRM5 (0.43) RAB9ANPC1GRM5CDC7DBF4
SCHEMBL279750 0.71 USP2 (0.43) POLBCASP3SENP8SENP7SENP6
SCHEMBL360187 0.71 GRM5 (0.47) POLBALDH1A1GRM5KMT2A
SCHEMBL10901370 0.71 L3MBTL1 (0.59) POLBALDH1A1HPGDL3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL POLB 4352/4885CASP3 1798/4885SENP8 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.